Can a patient take naltrexone while taking duloxetine (Cymbalta) or another selective serotonin reuptake inhibitor (SSRI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Naltrexone Be Taken with Cymbalta (Duloxetine) or SSRIs?

Yes, naltrexone can be safely taken with duloxetine (Cymbalta) or SSRIs—there are no contraindications or significant drug-drug interactions between these medications, and this combination is commonly used in clinical practice.

Key Safety Considerations

No Direct Pharmacologic Interaction

Naltrexone is an opioid receptor antagonist that does not affect serotonin reuptake mechanisms. The FDA drug label for Cymbalta 1 does not list naltrexone as a contraindication or significant drug interaction. The label specifically warns about serotonergic drugs (triptans, linezolid, lithium, tramadol, other SSRIs/SNRIs) but makes no mention of naltrexone.

Clinical Evidence Supporting Combination Use

For alcohol dependence with depression, the combination of naltrexone plus sertraline (an SSRI) has been specifically studied:

  • A 2010 trial demonstrated that sertraline plus naltrexone combination produced superior outcomes compared to either medication alone, with a 53.7% abstinence rate versus 21-27% for monotherapy 2
  • The combination showed fewer serious adverse events (11.9%) compared to other treatment groups (25.9% overall) 2
  • A 2009 study found the combination well-tolerated with comparable compliance rates, though efficacy benefits were less pronounced 3

For obesity management, multiple guidelines explicitly recommend naltrexone-bupropion combinations without restrictions regarding concurrent antidepressant use 4, 5, 6, 7, 5. The 2016 AACE guidelines specifically address depression comorbidity, stating that naltrexone-bupropion "should be used with caution in patients with obesity and depression or avoided if patients are taking medications for depression" 7—but this caution relates to the bupropion component (which is itself an antidepressant), not naltrexone.

Specific Monitoring Recommendations

When Using Naltrexone with Duloxetine/SSRIs:

  • Monitor for mood changes: All patients on antidepressants require monitoring for suicidal ideation, behavioral activation, and mood destabilization 8
  • Blood pressure and heart rate: If using naltrexone-bupropion formulation (not naltrexone alone), monitor cardiovascular parameters 4, 5
  • No serotonin syndrome risk: Unlike combinations of multiple serotonergic agents, naltrexone does not contribute to serotonin syndrome risk 1, 9

Important Contraindication to Remember:

Naltrexone is absolutely contraindicated with chronic opioid use 4, 5—this is the critical safety concern, not SSRI/SNRI combinations.

Clinical Context Matters

The combination is used in three main scenarios:

  1. Alcohol use disorder with comorbid depression: Evidence supports combined use 2
  2. Obesity management in patients on antidepressants: Guidelines permit this with appropriate monitoring 4, 5, 7
  3. Opioid dependence: Limited evidence but combination appears tolerable 10

Bottom Line Algorithm

Proceed with naltrexone + duloxetine/SSRI if:

  • Patient is NOT on chronic opioids
  • Patient does not have uncontrolled hypertension (if using naltrexone-bupropion formulation)
  • Patient does not have seizure disorder (if using naltrexone-bupropion formulation)
  • Standard monitoring for antidepressant therapy is in place

The combination is pharmacologically safe and clinically established, particularly for patients with alcohol dependence and depression where it may offer superior outcomes compared to monotherapy.

References

Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Guideline

american association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2016

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Research

Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: analysis of The FDA Adverse Event Reporting System (FAERS).

Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.